Thus, Fn14 is intensively tested as a drug target using monoclonal antibodies or immunotoxins targeted to Fn14 or fusion proteins encoding Fn14 decoy receptors, which improve pathology in various mouse models of disease, such as for lung tumors, triple‐negative breast cancer, tumor cachexia, and atherosclerosis (Yepes et al, 2005; Schapira et al, 2009; Michaelson et al, 2011; Wajant, 2013; Zhou et al, 2014; Johnston et al, 2015; Peng et al, 2018; Alvarez de Cienfuegos et al, 2020; Dancy et al, 2020; Wolf et al, 2021). This evidence concerns the gene TNFRSF12A and atherosclerosis.